The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in
newborns with refractory seizures. The overall hypothesis is that bumetanide, added to
conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated
medication, compared with conventional antiepileptic drugs alone.
Phase:
Phase 1
Details
Lead Sponsor:
Soul, Janet , M.D.
Collaborators:
Charles H. Hood Foundation Citizens United for Research in Epilepsy Harvard Catalyst- Harvard Clinical and Translational Science Center Mooney Family Initiative for Translational Studies in Rare Diseases, Boston Children's Hospital National Institute of Neurological Disorders and Stroke (NINDS) Translational Research Program, Boston Children's Hospital